Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

Part of paid clinical trials in Lake Success, New York.

Sponsor
Xencor, Inc.
Study ID
NCT07593092
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • XmAb541 — BIOLOGICAL
    Monoclonal Bispecific Antibody
  • XmAb808 — BIOLOGICAL
    Monoclonal Bispecific Antibody

Study Details

The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on participants' tumor outcomes.

Key Dates

First listed
May 18, 2026
Start date
Jun 30, 2026
Status verified
Aug 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
90 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation and Dose Expansion of XmAb541 and XmAb808

Primary Outcome Measure

Incidence of Adverse Events [ Time Frame: Day 1 to 2 years ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Xencor Investigative SiteLake SuccessNew York11042-
Xencor Investigative SiteNew YorkNew York10029-
Xencor Investigative SiteThe BronxNew York10461-
Xencor Investigative SiteFort WorthTexas76104-

Find similar trials in Lake Success, NY

Nationwide
Ovarian cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials
By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Xencor Investigative Site· Lake Success, NYXencor Investigative Site· New York, NYXencor Investigative Site· The Bronx, NYXencor Investigative Site· Fort Worth, TX

Related Studies